Lucid Diagnostics shares are trading higher after the company announced data from its ESOGUARD BE-1 prospective, international, multicenter, single-arm study conducted to clinically validate performance of the EsoGuard Esophageal DNA test on samples collected with the EsoCheck Esophageal Cell Collection Device for detection of esophageal precancer and esophageal adenocarcinoma in a screening population.
Portfolio Pulse from Benzinga Newsdesk
Lucid Diagnostics shares are trading higher following the announcement of positive data from its ESOGUARD BE-1 study, which validated the performance of the EsoGuard Esophageal DNA test for detecting esophageal precancer and adenocarcinoma.
July 02, 2024 | 12:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Lucid Diagnostics shares are trading higher after the company announced positive data from its ESOGUARD BE-1 study, validating the EsoGuard Esophageal DNA test for detecting esophageal precancer and adenocarcinoma.
The positive data from the ESOGUARD BE-1 study is a significant milestone for Lucid Diagnostics, as it validates the effectiveness of their EsoGuard Esophageal DNA test. This news is likely to boost investor confidence and drive the stock price higher in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100